Blood Glucose Device Market Scope
Blood Glucose Device is a medical device used to estimate the concentration of glucose in the blood. It could also be a strip of glucose paper dipped in a substance and measured in relation to a glucose chart. A small drop of blood is obtained by pricking the skin with a lancet and placed on a disposable test strip, which is read by the metre and used to calculate the blood glucose level. The level is then displayed in mg/dL or mmol/L units by the metre. People with type 1 diabetes, type 2 diabetes, latent autoimmune diabetes in adults (LADA), or gestational diabetes. A glucometer is used to test blood glucose levels on a regular basis as part of their treatment plan.
The Blood Glucose Device market study is segmented by Type (Continuous Glucose Monitoring Device (CGMs) and Self-Monitoring Blood Glucose System (SMBGs)), by Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes and Others) and major geographies with country level break-up.
The demand for Blood Glucose Device is increasing due to growing diabetes population with each passing day. The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market soon. Players are expected to concentrate on the creation of novel compounds, which would likely boost the worldwide market's growth throughout the forecast period. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Blood Glucose Device market throughout the predicted period.
Sanofi (France), Dexcom (United States), Medtronic (Ireland), Abbott Laboratories (United States), Senseonics Holdings (United States), Roche Holding AG (Switzerland), LifeScan, Inc. (Platinum Equity) (United States), Pulsatom Healthcare (India), Beurer (Germany) and B. Braun (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are One Drop (United States), PHC Holdings (Japan) and DarioHealth (United States).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AMA Research has segmented the market of Global Blood Glucose Device market by Type, Application and Region.
On the basis of geography, the market of Blood Glucose Device has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In September 2019 Sanofi announced the partnership with Abbott Laboratories. The two companies will take a unique strategy to work with clients by creating apps that combine the revolutionary FreeStyle Libre technology with insulin dosing data for future smart pens, insulin titration apps, and cloud software.
- Rapid Development in Use of Smart Devices and Smart Phones in Blood Glucose Device
- Rising Diabetic Patient Population
- Growing Adoption of Continuous Glucose Monitoring (CGM) Systems
- Increase in Awareness of Blood Glucose Device
- The Side-Effects of Using Device Kidney Disease, Heart Disease, Eye Involvement and Nerve Involvement
- Lack of Accuracy for Each Single Data Point in CGMs
- Blood Glucose Device and strips are Very Expensive
Key Target AudienceVenture and Capitalist, New entrants/investors, Hospitals, Clinics, Residential and End-use industries